Boditech Med Unveils Next-Generation Infectious Disease Diagnostic Platforms at ESCMID Global 2025
- Showcased point-of-care solutions for latent tuberculosis and infection differentiation using the AFIAS platform
- Introduced 'ichroma 50 Plus,' an automated high-throughput device for latent tuberculosis diagnosis
- Aiming to expand partnerships and accelerate sales growth in the European market
Boditech Med, a leader in point-of-care diagnostics, announced that it unveiled its latest infectious disease diagnostic platforms at ESCMID Global 2025, held in Austria.
Organized by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), ESCMID Global is the world’s largest academic event dedicated to infectious diseases and clinical microbiology, attracting over 15,000 professionals from around 100 countries to share the latest research and technological advancements.
At the event, Boditech Med presented a range of point-of-care solutions targeting:
• Sepsis and severe infections
• Antimicrobial resistance (AMR)
• Tuberculosis
• Gastrointestinal health
• Tropical and global infectious diseases
Among the highlights were the AFIAS IGRA-TB for latent tuberculosis diagnosis and AFIAS MxA/CRP for viral-bacterial infection differentiation. These products drew strong interest for their rapid turnaround time, simple procedures, and high clinical utility.
AFIAS IGRA-TB is a rapid test kit that quantifies interferon-gamma to determine latent tuberculosis infection in just 15 minutes, dramatically reducing the complexity and labor-intensiveness associated with traditional IGRA testing. Its intuitive workflow makes it an ideal solution for field-focused global health programs.
Also launched at the event, the ichroma 50 Plus is a high-throughput device that fully automates the latent tuberculosis diagnostic process. Users can simply load the samples, and the device's system handles all subsequent steps automatically, significantly shortening testing time and offering a seamless, efficient diagnostic environment.
Meanwhile, AFIAS MxA/CRP is a next-generation infectious disease differentiation platform that simultaneously measures MxA protein (a viral infection marker) and CRP (a bacterial infection marker) using whole blood. Results are available within 12 minutes, providing a faster and more cost-effective alternative to traditional PCR or blood culture tests. This solution is also recognized as a valuable tool for improving infection management and reducing inappropriate antibiotic prescriptions, which are major contributors to antimicrobial resistance.
During ESCMID Global 2025, Boditech Med also hosted a successful Boditech Med Expert Dinner Meeting, inviting leading infectious disease experts from around the world. The meeting fostered in-depth discussions on the clinical applicability and diagnostic accuracy of Boditech’s products and sparked new opportunities for international collaborative research and partnerships.
Eui-yeol Choi, CEO of Boditech Med, commented:
“Accurate and rapid diagnostics are the cornerstone of global infectious disease response. Through this event, we aim to expand our partnerships across Europe and accelerate our sales growth in the European market.”